"As Dr. Sathananthan has stated, these results do not come as a surprise. Extensive preclinical
work in partnership with a large number of leading physicians has demonstrated a superior
hemodynamic result compared to commercially available products, both in native aortic stenosis
and in valve-in-valve procedures. With a rapidly growing number of degenerating AVRs, this
valve will have a dominant role in treating these patients. “"
$3b market just for ViV!!!
Ann: Exceptional Results in Second Valve-in-Valve Case, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.00 |
Change
-0.030(0.50%) |
Mkt cap ! $92.99M | |||
| Open | High | Low | Value | Volume |
| $6.01 | $6.03 | $5.84 | $85.53K | 14.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 333 | $6.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.25 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |